Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

401 - 410 of 2196 results found

Reactive Infectious Mucocutaneous Eruptions (RIME) in COVID-19

Date
Friday, January 05, 2024 - 4:00 AM
Description
Reactive infectious mucocutaneous eruptions (RIME) is a relatively novel terminology describing postinfectious mucocutaneous eruptions that usually affect 2 or more mucosal sites. To our knowledge, we describe the first case of RIME secondary to

Remdesivir: treatment of COVID-19 in special populations

Date
Friday, January 05, 2024 - 4:00 AM
Description
Remdesivir (RDV) is the mainstay antiviral therapy for moderate to severe COVID-19. Although remdesivir was the first drug approved for COVID-19, information about its efficacy and safety profile is limited in a significant segment of the population

Recovering from the stress of the COVID-19 pandemic

Date
Friday, January 05, 2024 - 4:00 AM
Description
For our special issue on stress, we asked scientists about recovering from the stress of the pandemic, including some who shared insights with us in mid-2020. They discuss the importance of teamwork, reassessing priorities, and the added stresses of

Regulation of innate immune and inflammatory responses by supersulfides

Date
Friday, January 05, 2024 - 4:00 AM
Description
Innate immunity plays an important role in host defense against microbial infections. It also participates in activation of acquired immunity through cytokine production and antigen presentation. Pattern recognition receptors such as Toll-like